Dr Luis Paz-Ares speaks to ecancer at the European Lung Cancer Congress 2019 about an integrated analysis of the STARTRK-2, STARTRK-1 and ALKA-372-001 trials. Dr Paz-Ares outlines the mechanism of entrectinib in a genetically specific set of patients,...
Original Article: Entrectinib in NTRK fusion-positive non-small cell lung cancer